[1]
|
Wang, H. (2016) Anti-VEGF Therapy in the Management of Retinopathy of Prematurity: What We Learn from Repre-sentative Animal Models of Oxygen-Induced Retinopathy. Eye and Brain, 2016, 81-90.
https://doi.org/10.2147/EB.S94449
|
[2]
|
Mintz-Hittner, H.A., Kennedy, K.A. and Chuang, A.Z. (2011) Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity. New England Journal of Medicine, 364, 603-615. https://doi.org/10.1056/NEJMoa1007374
|
[3]
|
Simpson, J.L., Melia, M., Yang, M.B., et al. (2012) Current Role of Cryotherapy in Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology. Ophthalmology, 119, 873-877.
https://doi.org/10.1016/j.ophtha.2012.01.003
|
[4]
|
Hubbard III, G.B., Cherwick, D.H. and Burian, G. (2004) Lens-Sparing Vitrectomy for Stage 4 Retinopathy of Prematurity. Ophthalmology, 111, 2274-2277. https://doi.org/10.1016/j.ophtha.2004.05.030
|
[5]
|
Repka, M.X., Tung, B., Good, W.V., et al. (2006) Outcome of Eyes Developing Retinal Detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). Ar-chives of Ophthalmology, 124, 24-30.
https://doi.org/10.1001/archopht.124.1.24
|
[6]
|
Stahl, A., Lepore, D., Fielder, A., et al. (2019) Ranibizumab versus Laser Therapy for the Treatment of Very Low Birthweight Infants with Retinopathy of Prematurity (RAINBOW): An Open-Label Randomised Controlled Trial. Lancet, 394, 1551-1559. https://doi.org/10.1016/S0140-6736(19)31344-3
|
[7]
|
Eldweik, L. and Mantagos, I.M. (2016) Role of VEGF Inhi-bition in the Treatment of Retinopathy of Prematurity. Seminars in Ophthalmology, 31, 163-168. https://doi.org/10.3109/08820538.2015.1114847
|
[8]
|
Chan-Ling, T., Gole, G.A., Quinn, G.E., Adamson, S.J. and Darlow, B.A. (2018) Pathophysiology, Screening and Treatment of ROP: A Multi-Disciplinary Perspective. Progress in Retinal and Eye Research, 62, 77-119.
https://doi.org/10.1016/j.preteyeres.2017.09.002
|
[9]
|
Dvorak, H.F., Brown, L.F., Detmar, M. and Dvorak, A.M. (1995) Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angio-genesis. The American Journal of Pathology, 146, 1029-1039.
|
[10]
|
Prager, G.W., Breuss, J.M., Steurer, S., Mihaly, J. and Binder, B.R. (2004) Vascular Endothelial Growth Factor (VEGF) Induces Rapid Prourokinase (Pro-uPA) Activation on the Surface of Endothelial Cells. Blood, 103, 955-962.
https://doi.org/10.1182/blood-2003-07-2214
|
[11]
|
Mizukami, Y., Kohgo, Y. and Chung, D.C. (2007) Hypoxia In-ducible Factor-1–Independent Pathways in Tumor Angiogenesis. Clinical Cancer Research, 13, 5670-5674. https://doi.org/10.1158/1078-0432.CCR-07-0111
|
[12]
|
Goswami, B., Goyal, M., Beri, S., et al. (2015) Role of Se-rum Levels of Vascular Endothelial Growth Factor and Its Receptor in Retinopathy of Prematurity. Iranian Journal of Pediatrics, 25, e2373. https://doi.org/10.5812/ijp.2373
|
[13]
|
Chen, J. and Smith, L.E.H. (2007) Retinopathy of Prematurity. Angiogenesis, 10, 133-140.
https://doi.org/10.1007/s10456-007-9066-0
|
[14]
|
Smith, L.E.H. (2008) Through the Eyes of a Child: Understanding Retinopathy through ROP the Friedenwald Lecture. Investigative Ophthalmology & Visual Science, 49, 5177-5182. https://doi.org/10.1167/iovs.08-2584
|
[15]
|
Tran, K.D., Cernichiaro-Espinosa, L.A. and Berrocal, A.M. (2018) Management of Retinopathy of Prematurity—Use of Anti-VEGF Therapy. Asia-Pacific Journal of Ophthalmology, 7, 56-62.
|
[16]
|
Wu, A.-L. and Wu, W.-C. (2018) Anti-VEGF for ROP and Pediatric Retinal Diseases. Asia-Pacific Journal of Ophthalmology, 7, 145-151. https://doi.org/10.22608/201837
|
[17]
|
Kang, H.G., Choi, E.Y., Byeon, S.H., et al. (2018) Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatom-ical Outcomes. Korean Journal of Ophthalmology, 32, 451-458.
https://doi.org/10.3341/kjo.2018.0011
|
[18]
|
Kong, L., Bhatt, A.R., Demny, A.B., et al. (2015) Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants with Retinopathy of Prematurity. Investigative Oph-thalmology & Visual Science, 56, 956-961.
https://doi.org/10.1167/iovs.14-15842
|
[19]
|
Spandau, U. (2013) What Is the Optimal Dosage for Intravitreal Bevacizumab for Retinopathy of Prematurity? Acta Ophthalmologica, 91, e154. https://doi.org/10.1111/j.1755-3768.2012.02552.x
|
[20]
|
Wallace, D. K. (2016) Retinopathy of Prematurity: An-ti-VEGF Treatment for ROP: Which Drug And What Dose? Journal of AAPOS: The Official Publication of the American Association for Pediatric Ophthalmology and Strabismus, 20, 476-478.
|
[21]
|
Geloneck, M.M., Chuang, A.Z., Clark, W.L., et al. (2014) Refractive Outcomes Following Bevacizumab Monotherapy Compared with Conventional Laser Treatment: A Randomized Clinical Trial. JAMA Ophthalmology, 132, 1327-1333.
https://doi.org/10.1001/jamaophthalmol.2014.2772
|
[22]
|
Nicoară, S.D., Nascutzy, C., Cristian, C., et al. (2015) Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity. Journal of Ophthalmology, 2015, Article ID: 102582. https://doi.org/10.1155/2015/102582
|
[23]
|
Hoerster, R., Muether, P., Dahlke, C., et al. (2013) Serum Concentra-tions of Vascular Endothelial Growth Factor in an Infant Treated with Ranibizumab for Retinopathy of Prematurity. Acta Ophthalmologica, 91, e74-e75.
https://doi.org/10.1111/j.1755-3768.2012.02469.x
|
[24]
|
早产儿视网膜病变眼科管理对策委员会(日本眼科学会, 日本视网膜玻璃体学会, 日本小儿眼科学会, 日本眼科医会). 对于早产儿视网膜症的抗VEGF疗法的指南[J/OL]. 日本眼科学会杂志, 2020, 124(12).
https://www.nichigan.or.jp/member/journal/guideline/detail.html?%20ItemId=325&dispmid=909, 2023-05-05.
|
[25]
|
Sankar, M.J., Sankar, J. and Chandra, P. (2018) Anti-Vascular Endothelial Growth Factor (VEGF) Drugs for Treatment of Retinopathy of Prematurity. Cochrane Database of Systematic Reviews, No. 1. Article No. CD009734.
https://doi.org/10.1002/14651858.CD009734.pub3
|
[26]
|
Stewart, M.W., Rosenfeld, P.J., F Penha, F.M., et al. (2012) Pharmacokinetic Rationale for Dosing Every 2 Weeks versus 4 Weeks with Intravitreal Ranibizumab, Bevaci-zumab, and Aflibercept (Vascular Endothelial Growth Factor Trap-Eye). Retina, 32, 434-457. https://doi.org/10.1097/IAE.0b013e31822c290f
|
[27]
|
Sukgen, E.A., Söker, G., Koçluk, Y. and Gülek, B. (2017) Effect of Intravitreal Aflibercept on Central Retinal Arterial Blood Flow in Type 1 Retinopathy of Prematurity. European Journal of Ophthalmology, 27, 751-755.
https://doi.org/10.5301/ejo.5000938
|
[28]
|
Stahl, A., Sukgen, E.A., Wu, W.-C., et al. (2022) Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Random-ized Clinical Trial. JAMA, 328, 348-359.
https://doi.org/10.1001/jama.2022.10564
|
[29]
|
Vedantham, Va. (2019) Intravitreal Aflibercept Injection in Indian Eyes with Retinopathy of Prematurity. Indian Journal of Ophthalmology, 67, 884-888. https://doi.org/10.4103/ijo.IJO_708_18
|
[30]
|
Salman, A.G. and Said, A.M. (2015) Structural, Visual and Refractive Outcomes of Intravitreal Aflibercept Injection in High-Risk Prethreshold Type 1 Retinopathy of Prematurity. Ophthalmic Research, 53, 15-20.
https://doi.org/10.1159/000364809
|
[31]
|
Bai, Y., Nie, H., Wei, S., et al. (2019) Efficacy of Intravitreal Conbercept Injection in the Treatment of Retinopathy of Prematurity. The British Journal of Ophthalmology, 103, 494-498. https://doi.org/10.1136/bjophthalmol-2017-311662
|
[32]
|
Wu, Z., Zhao, J., Lam, W., et al. (2022) Comparison of Clinical Outcomes of Conbercept Versus Ranibizumab Treatment for Retinopathy of Prematurity: A Multicentral Pro-spective Randomised Controlled Trial. The British Journal of Ophthalmology, 106, 975-979. https://doi.org/10.1136/bjophthalmol-2020-318026
|
[33]
|
Autrata, R., Krejčířová, I., Šenková, K., et al. (2012) In-travitreal Pegaptanib Combined with Diode Laser Therapy for Stage 3+ Retinopathy of Prematurity in Zone I and Poste-rior Zone II. European Journal of Ophthalmology, 22, 687-694. https://doi.org/10.5301/ejo.5000166
|
[34]
|
Pertl, L., Steinwender, G., Mayer, C., et al. (2015) A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. PLOS ONE, 10, e0129383. https://doi.org/10.1371/journal.pone.0129383
|
[35]
|
Huang, Q. and Zhao, P. (2018) Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity. Annals of Eye Science, 2, Article No. 47. https://doi.org/10.21037/aes.2017.02.06
|
[36]
|
Azad, R., Gilbert, C., Gangwe, A.B., et al. (2020) Retinopathy of Prematurity: How to Prevent the Third Epidemics in Developing Countries. Asia-Pacific Journal of Ophthalmology, 9, 440-448.
https://doi.org/10.1097/APO.0000000000000313
|